Program
pumitamig
Also written as “Pumitamig”, “PM8002” and “BNT327”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.
Drug pagePumitamig: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTech | 2321 open or running | phase 3since May 14, 2024 | Feb 15, 2023 | Jan 1, 2027phase 2 · NCT05879055 |
| Bristol-Myers Squibbits history only | 99 open or running | phase 3since Oct 23, 2025 | Sep 26, 2024 | Mar 15, 2028phase 2 · NCT07871214 |
| Boehringer Ingelheimits history only | 11 open or running | phase 2since Sep 22, 2026 | Sep 22, 2026 | Apr 17, 2030phase 2 · NCT07843940 |
| DualityBioits history only | 11 open or running | phase 2since Apr 9, 2025 | Apr 9, 2025 | Jun 30, 2030phase 2 · NCT06953089 |
- Named in Bristol-Myers Squibb’s own pipeline as
pumitamig
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: MediLink Therapeutics (Suzhou), BioNTech (Shanghai) Pharmaceuticals and Genmab.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentBristol Myers Squibb develops it with BioNTech, worldwide, profits and losses shared equally.Announced Jun 2, 2025 · Source: BioNTech, Jun 2, 2025
How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.
History and studies of BioNTech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Feb 15, 2023.
- Jun 15, 20232 phase 2 studiesNCT05918133, NCT05918107
- May 14, 2024Phase 3 study in Triple Negative Breast NeoplasmsNCT06419621 · 392 enrolled · China
- Jun 3, 20242 phase 2 studiesNCT06449222, NCT06449209
- Aug 21, 2024Phase 2 study in Liver NeoplasmsNCT06584071 · 140 planned
- Sep 23, 2024Phase 3 study in SCLCNCT06616532 · 404 enrolled · China
- Nov 11, 20242 phase 3 studiesNCT06712355, NCT06712316
- Feb 10, 20252 phase 2 studiesNCT06827236, NCT06841055
- Feb 13, 2025Named pumitamigINNProposed as its International Nonproprietary Name in WHO's List 132 · before, PM8002, BNT327
- Mar 19, 2025Phase 2 study in Small Cell Lung CarcinomaNCT06892548 · 594 planned · United States, Australia, China and more
- Jun 2, 2025Bristol Myers Squibb develops it with BioNTechCo-developmentWorldwide, profits and losses shared equally · announced · BioNTech
- Jul 3, 20252 phase 2 studiesNCT07070232, NCT07079631
- Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07111520 · 880 planned · United States, Australia, China and more
- Sep 8, 2025Phase 3 study in Breast NeoplasmsNCT07173751 · 558 planned · United States, Argentina, Australia and more
- Dec 9, 2025Phase 2 study in GlioblastomaNCT07297212 · 75 planned · China
- Oct 14, 2026Primary completion moved from 2028-12 to 2029-04Date moved laterphase 3 · +4 months · NCT06712355
- Oct 22, 2026Primary completion moved from 2027-01-25 to 2027-05Date moved laterphase 3 · +4 months · NCT06616532
Ahead
- Jan 1, 2027Primary completion: phase 2 study in Neuroendocrine TumorsNCT05879055
- May 2027Primary completion: phase 3 study in SCLCNCT06616532
- Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06449209
- Jul 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT06419621
TargetBeta
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 23 BioNTech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297212Glioblastoma · China | 2 | Recruiting | Jan 2028 | 75 |
| NCT07173751Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Dec 2029 | 558 |
| NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 2 | Recruiting | Nov 2028 | 880 |
| NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more | 2 | Recruiting | Dec 2030 | 482 |
| NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more | 2 | Recruiting | Mar 2028 | 1,438 |
| NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more | 2 | Recruiting | Sep 2028 | 594 |
| NCT06841055Carcinoma, Non-Small-Cell Lung · United States, Australia, South Korea and more | 2 | Recruiting | Oct 2028 | 60 |
| NCT06827236Breast Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Aug 2029 | 380 |
| NCT06712355Small Cell Lung Carcinoma · United States, Australia, China and more | 3 | Recruiting | Apr 2029 | 621 |
| NCT06712316Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Jan 2029 | 1,580 |
| NCT06616532SCLC · China | 3 | Active, not recruiting | May 2027 | 404 |
| NCT06584071Liver Neoplasms | 2 | Not yet recruiting | Oct 2026 | 140 |
| NCT06449222Triple Negative Breast Neoplasms · United States, Australia, Turkey (Türkiye) and more | 2 | Active, not recruiting | Aug 2028 | 83 |
| NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more | 2 | Active, not recruiting | Jun 2027 | 110 |
| NCT06419621Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Jul 2027 | 392 |
| NCT05918133TNBC · China | 2 | Active, not recruiting | Oct 30, 2026 | 42 |
| NCT05918107MPM · China | 2 | Completed | Mar 31, 2026 | 31 |
| NCT05918445Neoplasms · China | 2 | Recruiting | Nov 30, 2025 | 380 |
| NCT05879068SCLC · China | 2 | Active, not recruiting | Apr 30, 2025 | 99 |
| NCT05879055Neuroendocrine Tumors · China | 2 | Active, not recruiting | Jan 1, 2027 | 31 |
| NCT05864105Carcinoma, Hepatocellular · China | 2 | Completed | Jul 24, 2025 | 35 |
| NCT05844150SCLC · China | 2 | Active, not recruiting | May 10, 2024 | 50 |
| NCT05756972NSCLC · China | 2 | Active, not recruiting | Sep 13, 2024 | 64 |
How it is read
Names in the registry
- “Pumitamig”, 18 entries
- “PM8002”, 11 entries
- “BNT327”, 3 entries
- “BNT327 Dose Level 1 (DL1)”, 2 entries
- “BNT327 Dose Level 2 (DL2)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Small Cell Lung Carcinoma, 4 studies
- Breast Neoplasms, 2 studies
- Carcinoma, Hepatocellular, 2 studies
- Colorectal Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.